Quviviq™ (daridorexant) – New drug approval
On January 10, 2022, Idorsia announced the FDA approval of Quviviq (daridorexant), for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Download PDF
